Regulatory Milestone Payment. Within [***] of the date upon which either BioNTech or Pfizer first obtains all Regulatory Approvals required for the Commercialization of the Product in a Major Market Country in the Territory, Pfizer shall pay BioNTech a one-time, non-refundable (without limiting Pfizer’s right to claim for damages under this Agreement) milestone payment of [***] Dollars (US$[***]) (“Regulatory Approval Milestone”), which shall be automatically applied to repayment of, and offset against, the BioNTech Deferred Development Costs, and to the extent that at such time the BioNTech Deferred Development Costs are less than the value of the Regulatory Approval Milestone any difference shall be paid to BioNTech.
Regulatory Milestone Payment. Within [***] days following [***] in the Territory, and receipt of an invoice therefor, Galderma shall pay Sol-Gel a one-time, non-refundable, non-creditable payment of [***]; provided, however, that Galderma shall not be obligated to make such payment in the event that, following the Refund Date, Galderma has given Sol-Gel notice of termination of this Agreement pursuant to Section 13.02 (Termination at Will by Galderma) and Regulatory Approval of the Licensed Product from the FDA in the Territory is received thereafter.
Regulatory Milestone Payment. The Sandoz Parties shall pay Momenta a one-time non-creditable, non-refundable milestone payment equal to [**] Dollars (U.S.$[**]) ("REGULATORY MILESTONE PAYMENT") on the earlier of (a) Final Legal Clearance or (b) U.S. Launch; PROVIDED, HOWEVER, THAT the Regulatory Milestone Payment is payable only if (i) Sandoz receives ANDA Final Approval for an EXECUTION COPY ANDA filed by Sandoz or any of its Affiliates for the Product before any Third Party (other than [**]) receives ANDA Final Approval for an ANDA filed by such Third Party for a Lovenox(R)-Equivalent Product, and (ii) (A) if U.S. Launch occurs prior to Final Legal Clearance, there is [**] in the U.S. Territory at the time of U.S. Launch, or (B) if Final Legal Clearance occurs prior to U.S. Launch, no Third Party (other than [**]) has received ANDA Final Approval for an ANDA filed by such Third Party for a Lovenox(R)-Equivalent Product at the time of Final Legal Clearance.
Regulatory Milestone Payment. Within the later of (a) [***] of the date upon which either BioNTech or Pfizer first obtains all Regulatory Approvals required for the Commercialization of the Product in a Major Market Country in the Territory or (b) following achievement of the milestone under (a) above [***] after the Amendment Signing Date, Pfizer shall pay BioNTech a one-time, non-refundable (without limiting Pfizer’s right to claim for damages under this Agreement) milestone payment of [***] US Dollars (US $[***]) (“Regulatory Approval Milestone”).
Regulatory Milestone Payment. 8.2 The Licensee will pay to the Licensor a milestone payment of five million USD (US$5,000,000) within thirty (30) days of the grant of Regulatory Approval in the USA for the Product for the Pediatric Indication.
Regulatory Milestone Payment. The Sandoz Parties shall pay Momenta a one-time non-creditable, non-refundable milestone payment equal to Five Million Dollars (U.S.$5,000,000) (“Regulatory Milestone Payment”) on the earlier of (a) Final Legal Clearance or (b) U.S. Launch; provided, however, that the Regulatory Milestone Payment is payable only if (i) Sandoz receives ANDA Final Approval for an ANDA filed by Sandoz or any of its Affiliates for the Product before any Third Party (other than [**]) receives ANDA Final Approval for an ANDA filed by such Third Party for a Lovenox®-Equivalent Product, and (ii) (A) if U.S. Launch occurs prior to Final Legal Clearance, there is [**] in the U.S. Territory at the time of U.S. Launch, or (B) if Final Legal Clearance occurs prior to U.S. Launch, no Third Party (other than [**]) has received ANDA Final Approval for an ANDA filed by such Third Party for a Lovenox®-Equivalent Product at the time of Final Legal Clearance.
Regulatory Milestone Payment. When the Product is approved with an indication for bacteremia in all five (5) of the countries, Germany, France, Italy, Spain, and the UK, Cardiome will make a one-time milestone payment of CHF [redacted] ([redacted] Swiss Francs) to Basilea within thirty (30) days of the milestone being met.
Regulatory Milestone Payment. Upon obtaining Regulatory Authority approval of the first JNDA for Licensed Product Covered by a Valid Claim of (1) the Eagle Licensed Patents or (2) the SymBio Collaboration Patents unless Section 8.2(c) applies, in each case ((1) and (2)) in the SymBio Territory, SymBio shall promptly notify Eagle and pay to Eagle a one-time, non-refundable and non-creditable milestone payment of [ * ] within thirty (30) days after such JNDA approval.
Regulatory Milestone Payment. (i) Subject to Section 2.1(d), if the Regulatory Milestone (EE) Event occurs on or before March 31, 2024, then the Company shall notify the Investors in writing of the occurrence of the Regulatory Milestone (EE) Event within five Business Days of the occurrence thereof, and, no later than 15 Business Days after receipt by the Investors of such written notice, each Investor shall pay (or cause to be paid) to the Company, severally but not jointly, by wire transfer of immediately available funds in U.S. dollars as directed by the Company in writing concurrent with the furnishing of such written notice, (A) if such Investor is an Initial Investor, the sum set forth opposite such Initial Investor’s name in the column entitled “Regulatory Milestone Payment” on Schedule 1.1 attached hereto plus any additional amount committed by such Investor as set forth in the written notice described in the last sentence of Section 2.1(b)(ii), and (B) if such Investor is an Additional Regulatory Milestone Investor, the portion of the Additional Regulatory Milestone Payment payable by such Additional Regulatory Milestone Investor. If the Regulatory Milestone (EE) Event does not occur on or before March 31, 2024, then no Investor shall be required to pay any amounts pursuant to this Section 2.1(b).
Regulatory Milestone Payment. Esperion will provide DSE with written notice of the achievement of the following regulatory milestone event within [***] days after such event has occurred. Esperion shall invoice DSE within [***] days of receipt of such written notice, and DSE shall pay the associated milestone payment within [***] days following receipt of such invoice. This milestone payment shall be payable only once. Regulatory Milestone Event Milestone Payment [***] [***] [***] [***] [***]
